We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Press & Announcements

Organogenesis Holdings Inc. to Present at Oppenheimer's 29th Annual Healthcare Conference

Canton, MA, March 11, 2019 – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in Oppenheimer's 29th Annual Healthcare Conference at the Westin New York Grand Central in New York, New York and present a corporate overview on Wednesday, March 20 at 2:10 p.m. Eastern Time.

A live audio webcast of the conference presentation will be accessible by visiting the "Upcoming Events" section on the "Investor Relations" page of Organogenesis's website www.organogenesis.com. An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis' comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

Investor Inquiries:

Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500

Press and Media Inquiries:

Organogenesis
Angelyn Lowe
alowe@organo.com
781-774-9364


« Back to Press Releases and Announcements